Electron spin resonance studies on caeruloplasmin and iron transferrin in patients with chronic lymphocytic leukaemia

Green, J A; Pocklington, T; Dawson, Audrey A.; Foster, Margaret A.

doi:10.1038/bjc.1980.58

Cited by 7 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of ceruloplasmin is increased in certain cancers (27)(28)(29) such as prostate cancer (30,31) and after estrogen administration (32,33). Copper-chelating agents (e.g., tetrathiomolybdate) lower ceruloplasmin levels and are potent antiangiogenic agents, but their clinical efficacy in the treatment of metastatic androgen-independent prostate cancer still awaits Each individual phage clone, allowed to circulate for 24 h in tumor-bearing animals, homed specifically to the androgen-independent prostate cancer xenograft.…”

Section: Discussionmentioning

confidence: 99%

Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors

Mandelin

Cardó-Vila

Driessen

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

We performed combinatorial peptide library screening in vivo on a novel human prostate cancer xenograft that is androgenindependent and induces a robust osteoblastic reaction in bonelike matrix and soft tissue. We found two peptides, PKRGFQD and SNTRVAP, which were enriched in the tumors, targeted the cell surface of androgen-independent prostate cancer cells in vitro, and homed to androgen receptor-null prostate cancer in vivo. Purification of tumor homogenates by affinity chromatography on these peptides and subsequent mass spectrometry revealed a receptor for the peptide PKRGFQD, α-2-macroglobulin, and for SNTRVAP, 78-kDa glucose-regulated protein (GRP78). These results indicate that GRP78 and α-2-macroglobulin are highly active in osteoblastic, androgen-independent prostate cancer in vivo. These previously unidentified ligand-receptor systems should be considered for targeted drug development against human metastatic androgen-independent prostate cancer.peptides | ligand receptors | phage display | GRP78 | tumor targeting A ndrogen deprivation remains the standard therapy for metastatic prostate cancer. Despite the favorable initial response, in most cases the disease progresses, becomes androgen-independent, and gives rise to soft tissue and osteoblastic bone metastases that ultimately lead to death (1, 2). Paradoxically, all currently available animal models of osteoblastic bone metastases are androgen dependent (3-6). The first (to our knowledge) human prostate cancer xenograft model that does not express androgen receptor but still induces a strong osteogenic response led Li et al. (7) to conclude that androgen receptor-null cells contribute to the castrate-resistant osteoblastic progression of prostate cancer and that targeting these cells will be critical in the treatment of prostate cancer bone metastases.In vivo phage display can be used to explore the surface of cells in their anatomical microenvironment (8)(9)(10)(11)(12)(13)(14). This technology enables the identification of molecular signatures that could allow targeted systemic delivery of therapeutic agents to cancer tissues (9,12,15,16). Using such methodology and the special prostate cancer model (7), we hypothesized that ligandreceptor pairs for targeting metastasizing androgen-independent prostate cancer cells could be identified.Here we select two novel ligand peptides that were selected in vivo from human androgen-independent prostate cancer xenografts. We show that they target the surface of an androgenindependent prostatic cell line in vitro and home to androgen receptor-null prostate tumors in vivo. With affinity chromatography, we next isolated their respective receptors, 78-kDa glucose-regulated protein (GRP78) and α-2-macroglobulin, from tumor lysates and as a proof of principle verified the peptide-GRP78 interaction in vitro with recombinant GRP78. These data confirm that GRP78 is a functional molecular target on prostatic cancer cell surfaces in vivo. Such ligand-receptor systems may be applicable to targeted therapy and should be...

show abstract

Section: Discussionmentioning

confidence: 99%

Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors

Mandelin

Cardó-Vila

Driessen

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…plasma, and serum are iron transferrin with a signal This value was estimated from a receiver-operating of g Å 4.2 and the copper ceruloplasmin with a signal of g Å 2.049 (2,(4)(5)(6)(7)(8)(9)(10)(11)(12)14). In the pleural effusions, we also observed the signals with g Å 4.2 and 2.049.…”

Section: Origin Of Fe 3/ and Cu 2/ Signals From The Pleuralmentioning

confidence: 92%

“…nance (ESR) 1 method on blood (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12). Some authors The peak-to-peak height was used as a measure of sighave reported that the patients with the malignant nal intensity, since the signal was confirmed to have diseases such as cancer and Hodgkin's disease had a constant line width and line shape in all the samples.…”

mentioning

confidence: 99%

Estimation of the Malignancy of Pleural Effusions by Electron Spin Resonance

Takeda

Haida

Shioya

et al. 1996

Analytical Biochemistry

View full text Add to dashboard Cite

Observations of serum trace elements in chronic lymphocytic leukemia

Béguin

Brasseur

Weber

et al. 1987

Cancer

View full text Add to dashboard Cite

Serum trace elements (STE) were measured in 50 patients with chronic lymphocytic leukemia (CLL) and 100 normal subjects. Copper was higher in patients than in controls (1.50 +/- 0.06 versus 1.10 +/- 0.02 micrograms/ml, P less than 0.001), increased steadily from Stage 0 to Stage 4 (P = 0.002), and correlated with the lymphocyte count and serum lactate dehydrogenase (P less than 0.01) but not with acute phase reactants. Zinc was lower in patients than in controls (0.94 +/- 0.03 versus 1.10 +/- 0.02 micrograms/ml, P less than 0.001). Zinc (NS), selenium (P = 0.039), and calcium (P = 0.033), were decreased in Stages 3-4 as compared to Stages 0-2. The copper-to-zinc ratio (CZR) increased continuously from Stage 0 to Stage 4 (P less than 0.001). Discriminant analysis between two groups, Stage 0-2 and Stage 3-4, based on serum copper, zinc, calcium, and protein levels, allowed for a correct classification of 94% of the patients. Moreover, the clinical staging of the remaining 6% was modified retrospectively according to the results of discriminant analysis. It was concluded that (1) serum copper and CZR are useful indices of the extent of disease, (2) they are independent of a nonspecific acute phase reaction, (3) STE determination could be helpful in the staging of a limited number of CLL patients, and (4) zinc deficiency could contribute to immune dysfunction in CLL.

show abstract

Electron spin resonance studies on caeruloplasmin and iron transferrin in patients with chronic lymphocytic leukaemia

Cited by 7 publications

References 15 publications

Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors

Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors

Estimation of the Malignancy of Pleural Effusions by Electron Spin Resonance

Observations of serum trace elements in chronic lymphocytic leukemia

Contact Info

Product

Resources

About